Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Biogen Safe Harbor This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, ...

3. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments.

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Biogen’s stock surged 46.6% to $290.99 in premarket trading, putting it on track to add over $13.5 billion in market capitalization. Shares of Eisai jumped 17% to the daily limit in Tokyo. Shares of ...

Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also ...